Myasthenia gravis: vizsgálatok itt: Csehország
6 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Where
- Brno, Prague 2
- Életkor
- 18 év and over
- People
- 199 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00 - 2/3. fázisCsak meghívásosEvaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
- Where
- Brno, Ostrava
- Életkor
- 2 év to 18 év
- People
- 12 worldwide
- Run by
- argenx
See details and how to joinNCT05374590 · EU 2023-507379-23-00 - 3. fázisTaking peopleA Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
- Where
- Ostrava, Prague
- Életkor
- 18 év to 80 év
- People
- 195 worldwide
- Run by
- Dianthus Therapeutics
See details and how to joinNCT07647510 · EU 2026-525298-38-00 - 3. fázisTaking peopleEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Where
- Prague 2
- Életkor
- 18 év and over
- People
- 264 worldwide
- Run by
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00 - 2/3. fázisTaking peopleA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
- Where
- Brno, Ostrava
- Életkor
- 2 év to 17 év
- People
- 12 worldwide
- Run by
- argenx
See details and how to joinNCT06392386 · EU 2023-506159-12-00 - 3. fázisTaking peopleStudy to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Where
- Brno
- Életkor
- 18 év to 80 év
- People
- 231 worldwide
- Run by
- Immunovant Sciences GmbH
See details and how to joinNCT07039916 · EU 2024-515979-35-00